Literature DB >> 17097188

Pharmacophore-based discovery of ligands for drug transporters.

Cheng Chang1, Sean Ekins, Praveen Bahadduri, Peter W Swaan.   

Abstract

The ability to identify ligands for drug transporters is an important step in drug discovery and development. It can both improve accurate profiling of lead pharmacokinetic properties and assist in the discovery of new chemical entities targeting transporters. In silico approaches, especially pharmacophore-based database screening methods have great potential in improving the throughput of current transporter ligand identification assays, leading to a higher hit rate by focusing in vitro testing to the most promising hits. In this review, the potential of different in silico methods in transporter ligand identification studies are compared and summarized with an emphasis on pharmacophore modeling. Various implementations of pharmacophore model generation, database compilation and flexible screening algorithms are also introduced. Recent successful utilization of database searching with pharmacophores to identify novel ligands for the pharmaceutically significant transporters hPepT1, P-gp, BCRP, MRP1 and DAT are reviewed and the challenges encountered with current approaches are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097188      PMCID: PMC1773055          DOI: 10.1016/j.addr.2006.09.006

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  108 in total

Review 1.  Drug transport and targeting. Intestinal transport.

Authors:  D M Oh; H K Han; G L Amidon
Journal:  Pharm Biotechnol       Date:  1999

2.  Structure and mechanism of the lactose permease of Escherichia coli.

Authors:  Jeff Abramson; Irina Smirnova; Vladimir Kasho; Gillian Verner; H Ronald Kaback; So Iwata
Journal:  Science       Date:  2003-08-01       Impact factor: 47.728

3.  Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1.

Authors:  Cheng Chang; K Sandy Pang; Peter W Swaan; Sean Ekins
Journal:  J Pharmacol Exp Ther       Date:  2005-04-21       Impact factor: 4.030

4.  Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.

Authors:  Charles S Morrow; Christina Peklak-Scott; Bimjhana Bishwokarma; Timothy E Kute; Pamela K Smitherman; Alan J Townsend
Journal:  Mol Pharmacol       Date:  2006-01-24       Impact factor: 4.436

5.  Identification of common functional configurations among molecules.

Authors:  D Barnum; J Greene; A Smellie; P Sprague
Journal:  J Chem Inf Comput Sci       Date:  1996 May-Jun

6.  Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.

Authors:  R W Robey; W Y Medina-Pérez; K Nishiyama; T Lahusen; K Miyake; T Litman; A M Senderowicz; D D Ross; S E Bates
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

7.  PARM: a practical utility for drug design.

Authors:  J Pei; J Zhou; G Xie; H Chen; X He
Journal:  J Mol Graph Model       Date:  2001       Impact factor: 2.518

Review 8.  Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents.

Authors:  Ahcène Boumendjel; Hélène Baubichon-Cortay; Doriane Trompier; Thomas Perrotton; Attilio Di Pietro
Journal:  Med Res Rev       Date:  2005-07       Impact factor: 12.944

Review 9.  Molecular mechanisms of drug reinforcement and addiction.

Authors:  D W Self; E J Nestler
Journal:  Annu Rev Neurosci       Date:  1995       Impact factor: 12.449

Review 10.  Progress in understanding the structure-activity relationships of P-glycoprotein.

Authors:  Terry R Stouch; Olafur Gudmundsson
Journal:  Adv Drug Deliv Rev       Date:  2002-03-31       Impact factor: 15.470

View more
  27 in total

1.  Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore.

Authors:  Sankar Manepalli; Laura M Geffert; Christopher K Surratt; Jeffry D Madura
Journal:  J Chem Inf Model       Date:  2011-09-02       Impact factor: 4.956

2.  Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter.

Authors:  Horace T B Ho; Yongmei Pan; Zhiyi Cui; Haichuan Duan; Peter W Swaan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-08-04       Impact factor: 4.030

Review 3.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

4.  Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies.

Authors:  Xiaowan Zheng; Lei Diao; Sean Ekins; James E Polli
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

5.  Ultra-High-Throughput Structure-Based Virtual Screening for Small-Molecule Inhibitors of Protein-Protein Interactions.

Authors:  David K Johnson; John Karanicolas
Journal:  J Chem Inf Model       Date:  2016-01-14       Impact factor: 4.956

Review 6.  Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.

Authors:  Avner Schlessinger; Matthew A Welch; Herman van Vlijmen; Ken Korzekwa; Peter W Swaan; Pär Matsson
Journal:  Clin Pharmacol Ther       Date:  2018-08-30       Impact factor: 6.875

Review 7.  Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).

Authors:  Yash A Gandhi; Marilyn E Morris
Journal:  AAPS J       Date:  2009-07-24       Impact factor: 4.009

8.  Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP).

Authors:  Zhongqi Dong; Sean Ekins; James E Polli
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

9.  SLC Transporters: Structure, Function, and Drug Discovery.

Authors:  Claire Colas; Peter Man-Un Ung; Avner Schlessinger
Journal:  Medchemcomm       Date:  2016-03-28       Impact factor: 3.597

10.  Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.

Authors:  Matthew D Hall; Noeris K Salam; Jennifer L Hellawell; Henry M Fales; Caroline B Kensler; Joseph A Ludwig; Gergely Szakács; David E Hibbs; Michael M Gottesman
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.